| |
Monday, May 19th |
|
7:00am-8:00am |
Medication Compliance
Special Interest Group (SIG)
Working Group Chair Breakfast Meeting
(Private)
Quality of Life Special
Interest Group (SIG) Working Group Chair Breakfast Meeting (Private)
Managed Care_PBM
Special Interest Group (SIG) Working Group Chair Breakfast (Private)
|
|
7:00am-8:00am |
Breakfast with the Experts |
 |
| |
- Gerry Oster PhD, Vice President, PAI,
Brookline, MA, USA
- Michael Drummond PhD, Director, Centre
for Health Economics, University of York, York, UK
- David Miller PhD, Head-Health
Outcomes, GlaxoSmithKline, Greenford, Middlesex, UK
- M. Haim Erder PhD, Director-Health
Economics & Epidemiology, Amgen, Inc., Thousand Oaks, CA, USA
|
|
8:00am-8:15am |
Welcome |
|
| |
Kevin Schulman MD, MBA, ISPOR 8th Annual
International Meeting Program Chair and Director, Center for Clinical
and Genetic Economics, Duke Clinical Research Institute, Duke
University, Durham, North Carolina, USA
ISPOR Service
Awards Presentation
Presented by: Peter Davey MD, FRCP, 2002-2003 ISPOR President and Head
of Pharmacoeconomics, University of Dundee, Dundee, Scotland, UK
Presidential Address
Peter Davey MD, FRCP, 2002-2003 ISPOR
President and Head of Pharmacoeconomics, University of Dundee, Dundee,
Scotland, United Kingdom
|
|
8:15am-9:45am |
First Plenary Session |
|
|
| |
NEW
MEDICAL TECHNOLOGY: WHAT WILL IT COST? CAN WE AFFORD IT?
Moderator: Kevin Schulman MD, MBA, ISPOR
8th Annual International Meeting Program Chair and Director, Center for
Clinical and Genetic Economics, Duke Clinical Research Institute, Duke
University, Durham, North Carolina, USA
Speaker: Frank Sloan PhD, Alexander McMahon
Professor of Health Policy and Management, Fuqua School of Business,
Duke University, Durham, NC, USA
Speaker: Mark Pauly PhD, Bendheim
Professor; Professor of Health Care Systems, Business and Public Policy,
Insurance and Risk Management, and Economics, The Wharton School,
University of Pennsylvania, Philadelphia, PA, USA
Speaker: Henry J. Aaron PhD, Senior Fellow,
Economic Studies, The Brookings Institution, Washington, DC, USA |
|
9:45am-10:30am |
Break,
Exhibits, Contributed Poster Presentations – Session I |
| |
Break
sponsored by JeSTARx |
|
|
|
10:30am-12:00pm |
Contributed Podium Presentations |
|
|
| |
|
| |
Moderator:
Joseph Capelleri PhD, MPH, Associate Director, Pfizer Inc,
Groton, CT, USA |
|
CV1 |
PATTERNS AND RISK FACTORS FOR NON-COMPLIANCE
WITH HMG-COA INHIBITORS IN A MANAGED CARE POPULATION
Yu AP, Nichol MB, University of Southern California, Los Angeles, CA,
USA
|
|
CV2 |
CHOLESTEROL GOAL
ATTAINMENT IN PATIENTS WITH DIABETES: EVIDENCE FROM MANAGED CARE
Menzin J1, Brown J1, Friedman M1, Saperia G2, Graham LA3, 1Boston
Health Economics, Inc, Waltham, MA, USA; 2Fallon Clinic/Saint Vincent
Hospital, Worcester, MA, USA; 3Pfizer, New York, NY, USA
|
|
CV3 |
INFLUENCE OF DIABETES
AND BASELINE ST-SEGMENT CHANGE STATUS ON THE COST-EFFECTIVENESS OF AN
EARLY INVASIVE VS. CONSERVATIVE STRATEGY FOR THE TREATMENT OF ACUTE
CORONARY SYNDROMES: APPLICATION OF A NET-BENEFIT REGRESSION APPROACH TO
DATA FROM THE TACTICS-TIMI 18 TRIAL
Mahoney EM1, Chu H1, Jurkovitz CT1, Cannon CP2, Alexander C3, Nag
S3, Weintraub WS1, 1Emory University School of Medicine, Atlanta, GA,
USA; 2Brigham and Women's Hospital/Harvard University, Boston, MA, USA;
3Merck & Co, Inc, West Point, PA, USA
|
|
CV4 |
EFFECTIVENESS OF
AMLODIPINE VS VALSARTAN UPON BLOOD PRESSURE CHANGE AND CONTROL AMONG
HYPERTENSIVE ADULTS
McLaughlin T1, Tang SS2, Roberts C3, Battleman DS2, 1NDCHealth, Phoenix,
AZ, USA; 2Pfizer, Inc, New York, NY, USA; 3NDCHealth, Yardley, PA, USA
|
|
|
METHODOLOGY ISSUES |
|
|
Moderator:
Karen Rascati RPh, PhD, Professor, University of Texas, College
of Pharmacy, Austin, TX, USA |
|
MD1 |
AN ECONOMETRIC
APPROACH TO GENERATING POPULATION COST ESTIMATES FOR EVENT-TIME DATA: AN
EXAMPLE USING RENAL TRANSPLANT GRAFT FAILURE DATA
Irish W1, Sherrill B2, 1RTI Health Solutions, Durham, NC, USA;
2RTI Health Solutions, Research Triangle Park, NC, USA
|
|
MD2 |
COMPARISON OF PATIENT
SELF-REPORTED HEALTHCARE RESOURCE UTILIZATION TO ELECTRONIC RECORD DATA:
LESSONS LEARNED FROM A STUDY OF HERPES ZOSTER PATIENTS
Itzler R1, Choo P2, Bauer M3, Bulotsky M1, Canning C4, Coplan P1,
Nikas A1, Pellissier J1, 1Merck Research Laboratories, Blue Bell, PA,
USA; 2Channing Laboratory, Boston, MA, USA; 3Vanguard Medical
Associates, Watertown, MA, USA; 4Harvard Medical School and Harvard
Pilgrim Health Care, Boston, MA, USA
|
|
MD3
|
THE IMPACT OF
REQUIRING A FIXED PERIOD OF ELIGIBILITY IN ECONOMIC AND EPIDEMIOLOGICAL
STUDIES THAT UTILIZE LONGITUDINAL DATA
Eaton SC1, McQuay LJ1, Clark DW2, Paul JE1, Hauber AB3, 1RTI
Health Solutions, Research Triangle Park, NC, USA; 2GlaxoSmithKline,
Inc, Research Triangle Park, NC, USA; 3RTI Health Solutions, Hatboro,
PA, USA
|
|
MD4 |
AUTOMATING ECONOMIC
ANALYSIS OF CO-MEDICATION USE IN CLINICAL TRIALS
Waldeck R1, Kawabata H2, Yuan Y2, 1Bristol-Myers Squibb,
Wallingford, CT, USA; 2Bristol-Myers Squibb, Princeton, NJ, USA |
|
|
QUALITY OF LIFE/PATIENT PREFERENCES |
|
|
Moderator:
Daniel Polsky PhD, Research Associate Professor, University of
Pennsylvania, Philadelphia, PA, USA |
|
QL1 |
RELATIONSHIP BETWEEN
QUALITY OF LIFE, UTILITY, AND WILLINGNESS TO PAY IN PATIENTS WITH
DIABETES
Powers C, Suh DC, Shin H, Rutgers University, Piscataway, NJ, USA
|
|
QL2 |
CLINICAL IMPROVEMENT
AND RESPONSIVENESS OF PHYSICAL FUNCTION MEASURES: TREATMENT WITH CTLA4IG
(BMS-188667) IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
Li T, Williams GR, L'Italien G, Kawabata H, Nuamah I,
Bristol-Myers Squibb, Princeton, NJ, USA |
|
QL3 |
DIABETIC PATIENTS’
WILLINGNESS TO PAY FOR DIABETES EDUCATION BY PHARMACISTS: VALIDITY OF
CONTINGENT VALUATION METHOD
Suh DC, Powers C, Shin H, Rutgers University, Piscataway, NJ, USA
|
|
QL4 |
SMOKING STATUS AND
HEALTH-RELATED QUALITY OF LIFE (HRQOL): FINDINGS FROM THE BEHAVIORAL
RISK FACTOR SURVEILLANCE SYSTEM (BRFSS) DATA
Mody RR, Smith MJ, West Virginia University, Morgantown, WV, USA
|
|
|
PEDIATRICS |
|
|
Moderator: Mark
Nuijten MD, MBA, Director of European Business Development,
MEDTAP International, Molenpad, The Netherlands |
|
PD1 |
SUICIDE ATTEMPTS BY
ADOLESCENTS: HOSPITAL RESOURCE USE AND COSTS
O'Brien JA, Pitoniak-Morse CA, Caro J, Caro Research Institute,
Concord, MA, USA
|
|
PD2 |
A RANDOMIZED
CONTROLLED TRIAL OF A DRUG USE REVIEW INTERVENTION FOR ANTIBIOTICS
MEDICATIONS FOR OTITIS MEDIA
Lee Y, Christensen DB, University of North Carolina at Chapel
Hill, Chapel Hill, NC, USA
|
|
PD3 |
RELIABILITY AND
VALIDITY OF KINDL CHILDREN GENERIC HEALTH-RELATED QUALITY OF LIFE
QUESTIONNAIRE IN AN ASIAN SCHOOL-BASED SAMPLE
Hwee Lin W, Shu Chuen L, National University of Singapore,
Singapore, Republic of Singapore
|
|
PD4 |
LONGITUDINAL
EXAMINATION OF OUTCOMES ASSOCIATED WITH BOTULINUM TOXIN USE IN CHILDREN
WITH CEREBRAL PALSY
Balkrishnan R, Camacho F, Smith BP, Koman AL, Wake Forest University
School of Medicine, Winston-Salem, NC, USA
|
|
12:00pm-1:00pm |
Lunch,
Exhibits, Contributed Poster Presentations - Session I |
| |
Lunch sponsored by Caro Research |
|
|
|
1:00pm-2:00pm |
Issues Panels |
|
|
| |
Defining a cost-effectiveness acceptability criterion: Is one
needed? How should it be identified?
Chair:
A. Mark Fendrick MD,
Associate Professor, University of Michigan Medical Center, Ann Arbor,
MI, USA
Panelists: Marc Botteman MA,
Executive Director, Abt Associates, HERCULES, Bethesda, MD, USA;
Andrew Briggs PhD, Health Economics Research Centre, University
of Oxford, Institute of Health Sciences, Oxford
UK;
Rich Hirth PhD, Associate Professor, University of Michigan,
School of Public Health, Ann Arbor, MI, USA
This issues
panel will discuss the value and appropriateness of defining CEA
thresholds for health care decisionmakers. The same benchmarks - with no
real basis in science - continue to be cited decade after decade despite
a lack of strong evidence that they are a key element in the
decisionmaking
process. Moreover, these oft-noted thresholds have not been updated for
factors such as inflation, income growth, or changes in the capability
of medicine or societal preferences. Continued adherence to outdated
thresholds threatens the credibility of economic evaluations.
FDA's frequently asked questions for outcomes research during the
drug approval process and how the industry should prepare to
answer them
Chair:
Richard
Willke PhD,
Senior Director, Global Health Economics, Pharmacia, Peapack, NJ, USA
Panelists:
Laurie Burke RPh, FDA, Rockville, MD,
USA; Kati Copley-Merriman MS,MBA,
Senior Director/Site Leader, Global Outcomes Research, Pfizer,Inc,Ann
Arbor, MI, USA; Patrick Marquis MD, MBA,
Managing Director, MAPI Values, Boston, MA, USA;
Jane A. Scott PhD, Social Science
Analyst, Study Endpoints and Label Development (SEALD), US FDA,
Rockville, MD, USA
This issues panel
will conduct a mock end-of-phase II meeting at which several health
outcomes endpoints will be proposed for labeling. Answers to
both company and FDA questions will be presented.
Combination
Products: The Role of Outcomes Research
Chairs:
Greg de Lissovoy PhD, MPH, Vice
President, MEDTAP International, Bethesda, MD, USA and
Seema Sonnad PhD, Department of
Surgery, University of Pennsylvania, Philadelphia, PA, USA
Panelists: Mark Kramer,
Director, Office of Combination Products United States Food & Drug
Administration, Rockville, MD, USA; Paul
Marshall, Director, Health Economics, Cordis Corporation,
Division of Johnson & Johnson, Warren, NJ, USA.
Drug-device
combination products are increasingly important in health care. This
session will explore application of health economics and outcomes
research methods that are often quite distinct for drugs and devices to
combination products
Bayesian Statistics: Barriers to Acceptance by Decision-Makers
Chair:
Bryan Luce PhD, MBA, Senior Research
Leader & CEO, MEDTAP International, Bethesda, MD, USA
Panelists:
Anthony O’Hagan BBc, PhD, Professor of
Statistics, University of Sheffield, Sheffield, UK;
Steven Sheingold PhD, Senior
Economist, Health Care Financing Administration, Baltimore, MD, USA
This issue panel
reviews the Bayesian statistical approach to developing and presenting
evidence for decision makers, the benefits of and barriers to such an
approach
|
|
2:00pm-5:00pm |
ISPOR Student Council Mock
Interview Session |
|
|
|
2:00pm-2:15pm |
Break
Break Sponsored by JeSTARx |
|
|
|
2:15pm-3:15pm |
Contributed Workshops –
Session I |
|
|
| |
Quality
of Life/Patient-Reported Outcomes/Valuation Issues
|
|
WW1 |
CAN THE SF-36 BE USED IN CALCULATING
QALYS?
Lee TA1, Hollingworth W2, Kind P3, 1Hines VA Hospital, Hines, IL, USA;
2University of Washington, Seattle, WA, USA; 3University of York, York,
UK |
|
WW17 |
COMBINING
QUALITATIVE AND QUANTITATIVE TECHNIQUES IN THE DEVELOPMENT OF
PATIENT-REPORTED OUTCOME MEASURES
Fehnel SE, McLeod LD, Williams VSL, RTI Health Solutions, Research
Triangle Park, NC, USA.
|
|
|
Healthcare Policy Issues |
|
WW3 |
MEDICARE
REIMBURSEMENT TRENDS AND THEIR IMPACT ON PRODUCT PLANNING
Simison D, Robinson S, PharmAnalysis Group, Inc.,
Alexandria, VA, USA |
|
|
Outcomes Research – Practical Application Issues |
|
WW4 |
RISK
MANAGEMENT PRIMER AND INTRODUCTION TO NEW INFORMATION SOURCES AND TOOLS
Morris LS, IMS Health, Plymouth Meeting, PA, USA |
|
WW5 |
PRACTICAL
DECISION ANALYSIS FOR THE DECISION MAKER
Brixner DI1, Malone DC2, Avey SG3, 1University of
Utah, Salt Lake City, UT, USA; 2University of Arizona, Tucson, AZ, USA;
3Foundation of Managed Care Pharmacy, Alexandria, VA, USA |
|
WW6 |
INCORPORATING HEALTH OUTCOMES INTO THE DRUG DEVELOPMENT PROCESS:
OPTIMIZING YOUR HEALTH OUTCOMES STRATEGY
Brod M1, Swindle R2, 1The Brod Group, Mill Valley, CA,
USA; 2Eli Lilly and Company, Indianapolis, IN, USA |
|
|
Cost
Study Issues |
|
WW7 |
IN SEARCH
OF AN UNBIASED ESTIMATE OF TREATMENT EFFECT USING OBSERVATIONAL DATA: A
COMPARISON OF PROPENSITY SCORING AND HECKMAN TWO STAGE SAMPLE SELECTION
MODELS.
Ganguly R1, Martin BC1, Dorfman JH1, Rizzo JA2,
1University of Georgia, Athens, GA, USA; 2Cornell University, Ithaca,
NY, USA |
|
WW8 |
PHARMACOGENOMICS AND ECONOMIC ANALYSIS
Bala MV1, Zarkin GA2, Mauskopf JA2, 1Centocor, Inc, Malvern, PA,
USA; 2RTI Health Solutions, Research Triangle Park, NC, USA |
| 3:15pm-3:30pm |
Break |
| |
Break Sponsored by JeSTARx |
|
|
| 3:30pm-4:30pm |
Contributed Workshops –
Session II |
|
|
| |
Quality
of Life/Patient-Reported Outcomes/Valuation Issues |
|
WW9 |
VALUING
EQ-5D HEALTH STATES: METHODS AND RESULTS
de Charro F1, Kind P2, 1Erasmus University, Rotterdam,
Netherlands; 2University of York, York, UK |
|
WW10 |
UNDERSTANDING TREATMENT SATISFACTION: THE WHO, WHAT, WHERE, WHEN AND HOW
OF INCORPORATING TS AS A CONCEPTUALLY SOUND AND VALID PRO
Brod M1, Skovlund SE2, 1The Brod Group, Mill Valley, CA,
USA; 2Novo Nordisk, Bagsvaerd, Copenhagen, Denmark |
|
WW11 |
NEEDS-BASED QUALITY OF LIFE ASSESSMENT
McKenna SP, Doward LC, Galen Research, Manchester, UK |
|
|
Healthcare Policy Issues |
|
WW12 |
STANDARDIZING COST-EFFECTIVENESS ANALYSIS: THE CHOICE PROJECT IN THE
WORLD HEALTH ORGANIZATION
Tan-Torres Edejer T, Baltussen R, Lauer J,
Hutubessy R, World Health Organization, Geneva, Switzerland |
|
|
Outcomes Research – Practical Application Issues |
|
WW13 |
RISK
MANAGEMENT: IMPLICATIONS FOR FORMULARY DECISION-MAKING FROM RISK-BENEFIT
TO COST-EFFECTIVENESS
Shaya FT1, Mullins CD1, Wong W2, 1University of
Maryland School of Pharmacy, Baltimore, MD, USA; 2CareFirst BlueCross
BlueShield, Baltimore, MD, USA |
|
WW14 |
ACTIVITY-BASED COSTING: APPLICATIONS AND IMPLEMENTATION
Schmier JK, Halpern MT, Fernandez JE, Exponent, Alexandria, VA,
USA |
|
|
Cost
Study Issues |
|
WW15 |
BUDGETARY
IMPACT ANALYSES FOR STATE MEDICAID PROGRAMS: ONE MODEL OR FIFTY?
Menzin J1, Harnett J2, 1Boston Health Economics, Inc,
Waltham, MA, USA; 2Pfizer, Inc, New York, NY, USA |
|
WW16 |
USE OF
HEALTH INSURANCE CLAIMS DATA TO BUILD CLINICAL PATHWAYS MODELS FOR
PHARMACOECONOMIC
EVALUATION
Huse D, McGarry LJ, Innovus Research, Inc, Medford, MA,
USA |
| 4:30pm-5:00pm |
Break |
| |
Break Sponsored by JeSTARx |
|
|
| 5:00pm-6:00pm |
ISPOR Forums |
|
|
| |
Student Forum |
| |
Interviewing for a Career in Pharmacoeconomics and Outcomes Research:
A discussion on interviewing for careers in academia, consulting, and
the pharmaceutical industry with experts in their respective fields.
|
| |
Speakers: Kem Krueger PharmD, PhD,
Auburn University, Auburn, AL, USA; Karen Rascati RPh, PhD, University
of Texas, Austin, TX, USA; Bryan Luce PhD, MBA, MEDTAP International,
Bethesda, MD, USA; Rob Hauser PharmD, Institute for Advanced Studies
in Aging & Geriatric Medicine, Bethesda, MD, USA;
Ron
Ozminkowski PhD,
The MEDSTAT Group, Inc, Ann Arbor, MI, USA; Christopher Castin,
Morristown, PA, USA; Sandeep Duttagupta PhD, Pfizer Inc., New York,
NY, USA; Mohammed Omar PhD, RPh, Novartis Pharmaceuticals Corporation,
East Hanover, NJ, USA
|
| |
Medication Compliance Special Interest Group Forum |
| 5:00 – 5:05 |
Moderator:
Joyce Cramer BS, Medication Compliance SIG Chair and Associate
Research Scientist, Yale University School of Medicine, Department of
Psychiatry, Westhaven, CT, USA |
| 5:05 – 5:15 |
Speaker:
Michael B. Nichol PhD, Analyses Standards Working Group Chair and
Department of Pharmaceutical Economics & Policy Chair, University of
Southern California, Los Angeles, CA, USA |
| 5:15 – 5:25 |
Speaker: Peter K. Wong PhD, MBA, RPh, Issues & Methods Definitions
Working Group Chair and Vice President, Clinical Effectiveness & PI,
Good Samaritan Hospital, Dayton, OH, USA
The medication compliance and treatment persistence definitions
established by this Issues & Methods Definitions Working Group and the
related issues and methods they are working on will be presented. |
| 5:25 – 5:35 |
Speaker: Jasmanda H. Wu PhD, MPH, MBA Bibliography Working Group
Chair and Epidemiologist, Aventis Pharmaceuticals, Somerset, NJ, USA
A summary of report citations related to medication compliance,
treatment persistence and implications for health outcomes compiled by
the Bibliography Working Group, will be presented. |
| 5:35 – 5:45 |
Speaker: Andrea Adamus, PhD, Education Working Group Co-Chair and
Research Specialist, Department of Pharmacoeconomics, Division of
Pharmacy, University of Texas M.D. Anderson Cancer Center, Houston, TX,
USA
The plans for educating providers and users of health outcomes data on
the implications of medication compliance and treatment persistence
issues developed by the Education Working Group will be presented. |
| 5:45 – 5:55 |
Speaker: Tamas Andras Koncz PhD, Economics of Compliance Working
Group Chair and Health Economist, AARDEX Ltd., Zug, Switzerland
The progress and plans toward developing definitions of costs related to
medication compliance and treatment persistence by the Economics of
Compliance Working Group will be presented. |
| 5:55 – 6:00 |
Moderator: Joyce Cramer BS, Medication
Compliance SIG Chair and Associate Research Scientist, Yale University
School of Medicine, Department of Psychiatry, Westhaven, CT, USA
Closing Remarks
|
| |
Medication Compliance Sig: Issues & methods definitions working group
meeting |
| 6:00-7:00 |
Speaker:
Peter K. Wong PhD, MBA, RPh, Issues & Methods Definitions Working Group
Chair and Vice President, Clinical Effectiveness & PI, Good Samaritan
Hospital, Dayton, OH, USA
|
| |
Quality of Life Special Interest Group
Forum |
| 5:00 – 5:05 |
Moderator: Pennifer Erickson PhD,
Quality of Life SIG Chair and Co-founder, Online Guide to Quality of
Life Assessment (OLGA), State College, PA, USA
During this forum the five QOL Working Groups will present their goals,
accomplishments, activities and future plans. |
| 5:05-5:15 |
Speaker: Eva Lydick PhD, Population
Health Working Group Chair and Director of Epidemiology, AstraZeneca,
Wilmington, DE, USA
An update on the WHO information exchange between methodologists and
policy makers within the context of QALY measures of population health
will be presented. |
| 5:15-5:25 |
Speaker: Diane Wild MSc, Cross-Cultural
& Translational Adaptation Working Group Chair and Partner, Oxford
Outcomes Headington, Oxford, UK
The Cross-Cultural & Translational Adaptation Working Group drafted a
best practices checklist on the use of outcome measures in different
cultures and across languages. Issues regarding the way that measures
are developed, translated, and culturally adapted will be presented. |
| 5:25-5:35 |
Speaker: Michael Friedman PhD, Analysis
& Interpretation Working Group Chair and Director of Biostatistics,
Purdue Pharma, Stamford, CT, USA
The Analysis & Interpretation Working Group is focusing on clinical
significance of QOL measures and other patient-related outcomes and will
present their recent literature review on methodological articles.
|
| 5:35-5:45 |
Speaker: Margaret Rothman PhD, Concepts
& Definitions Working Group Chair and Executive Director of Health
Economics, Johnson & Johnson Pharmaceutical Research & Development,
Raritan, NJ, USA
The Concepts & Definitions Working Group’s monograph on Health Related
Quality of Life (HRQOL), soon to be published in the ISPOR Health Care
Cost, Quality, Outcomes: ISPOR Book of Terms, will be presented. |
| 5:45-5:55 |
Speaker: Pennifer Erickson PhD (for
John Brazier PhD), Values & Valuation Working Group and Professor of
Health Economics, ScHARR, University of Sheffield, Sheffield, UK
The Values & Valuation Working Group plans to create a Web-based digest
of articles on issues related to the valuation of QOL measures will be
presented. |
| 5:55-6:00 |
Moderator:
Pennifer Erickson PhD, Quality of Life SIG Chair and Co-founder, Online
Guide to Quality of Life Assessment (OLGA), State College, PA, USA
Closing Remarks
|
| |
Quality of Life Special Interest Group Breakout
Sessions |
| 6:00pm–7:00 pm |
These
sessions allow Annual Meeting attendees to speak informally with the
Chair and Core group members of a specific QoL SIG working group
|
Population Health Working Group Breakout Session |
|
Cross-Cultural & Translational Adaptation Working Group Session |
|
Values & Valuation Working Group Breakout Session |
|
Concepts & Definitions Working Group Breakout Session |
|
Analysis & Interpretation Working Group Breakout Session
|
|
| 6:00pm-8:00pm |
Exhibitors’ Open House
Reception & Contributed Poster Presentations (Session I)
Reception sponsored by MEDTAP
International |
|
7:00pm-8:00pm |
ISPOR Learning Outcomes Task Force Core Group Meeting (Private) |
|
7:00pm-8:00pm |
ISPOR Internet Education Steering Group Meeting (Private) |
|
7:30pm-9:00pm |
Value in Health Editorial Advisory Board Dinner (Private) |
| |
|
|
